Holder evidence
29
SEC ownership of 60 DEGREES PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001946563.
Lead holder
INTRACOASTAL CAPITAL, LLC
13D/G signal
INTRACOASTAL CAPITAL, LLC
Latest evidence
31 Mar 2026
- SEC evidence mix
- 13D/G, 3/4/5, and 13F
- Lead holder
- INTRACOASTAL CAPITAL, LLC
- Latest large-stake holder
- INTRACOASTAL CAPITAL, LLC
- Latest evidence date
- 31 Mar 2026
- CIK
- 0001946563
- Symbol
- SXTP, SXTPW on Nasdaq
- Location
- Washington, DC
Ownership snapshot
4 facts
Issuer identity
3 facts
Ownership snapshot
Top shareholders of 60 DEGREES PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
INTRACOASTAL CAPITAL, LLC
13D/G signal
INTRACOASTAL CAPITAL, LLC
Evidence rows
29
Latest as of
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.1%
13D/G row: INTRACOASTAL CAPITAL, LLC
Showing 1-8 of 29 holder rows.
Rank 1 holder
INTRACOASTAL CAPITAL, LLC
13D/G
- Ownership
- 9.1%
- Position
- $339.5K
Rank 2 holder
CVI Investments, Inc.
13D/G
- Ownership
- 7%
- Position
- $255.3K
Rank 3 holder
ARMISTICE CAPITAL, LLC
13D/G
- Ownership
- 5%
- Position
- $226.7K
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
9.1%
|
$339,474
263,158 shares
|
-$248,179 | 31 Mar 2026 |
| CVI Investments, Inc. |
13D/G
|
7%
|
$255,305
197,911 shares
|
$0 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$226,656
77,357 shares
|
$0 | 31 Mar 2025 |
| Orca Capital AG |
13D/G
|
4.9%
|
$382,327
166,229 shares
|
$0 | 15 Jul 2025 |
| Ayrton Capital LLC |
13D/G
|
4.1%
|
$260,977
177,427 shares
|
+$20,515 | 30 Sep 2025 |
| Cheryl Xu |
3/4/5
Director
|
0.37%
|
$45,866
15,816 shares
|
+$14,410 | 03 Jun 2025 |
| Knight Therapeutics Inc. |
3/4/5
Former 10% Owner
|
—
mixed-class rows
|
$5,475,241
1,232,700 shares
mixed-class rows
|
— | 28 Jul 2023 |
| KENTUCKY TECHNOLOGY INC. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$196,875
525,000 shares
|
— | 11 Jul 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$34,374.
Buys
$34,374
Insiders: 2
Sells
$0
Insiders: 0
Net
+$34,374
Shares: +27,633
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 27,633
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 22,633 | 0 | $19,964 | $0 | +$19,964 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 5,000 | 0 | $14,410 | $0 | +$14,410 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to 60 DEGREES PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Lead holder
Knight Therapeutics Inc.
Net 12M change
+$34,374
Latest report
13 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Knight Therapeutics Inc. | Former 10% Owner | $5,475,241 | Mixed | 28 Jul 2023 | ||
| KENTUCKY TECHNOLOGY INC. | 10%+ Owner | $196,875 | Mixed | 11 Jul 2023 | ||
| Florida State University Research Foundation Inc. | 10%+ Owner | $151,875 | Mixed | 11 Jul 2023 | ||
| Geoffrey S. Dow | President and CEO, Director | $47,837 | +$19,964 | +72% | Filing P/S | 15 Dec 2025 |
| Cheryl Xu | Director | $45,866 | +$14,410 | +46% | Filing P/S | 03 Jun 2025 |
| Tyrone Miller | Cfo | $38,237 | Mixed | 17 Jan 2025 | ||
| Kristen Landon | Chief Operating Officer | $11,713 | Mixed | 17 Jan 2025 | ||
| Charles W. Allen | Director | $4,622 | Mixed | 31 Dec 2023 | ||
| Stephen Toovey | Director | $4,014 | Mixed | 31 Dec 2023 | ||
| Paul Field | Director | $4,014 | Mixed | 31 Dec 2023 | ||
| Bryan Lee Smith | Chief Medical Officer | Mixed | 11 Jul 2023 | |||
| Eric Francois | Director | Mixed | 13 May 2026 |
Recent insider transactions for 60 DEGREES PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 19.4% | $7,759 | $0.8024 | 9,670 | 59,618 | 15 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 7.8% | $3,318 | $0.9184 | 3,613 | 49,948 | 11 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Purchase | 25.3% | $8,886 | $0.9504 | 9,350 | 46,335 | 10 Dec 2025 | Direct |
| Geoffrey S. Dow | SXTP | Common Stock | Award | 27.5% | 7,201 | 33,372 | 12 Sep 2025 | Direct | ||
| Geoffrey S. Dow | SXTP | Common Stock | Award | 20.1% | 4,376 | 26,171 | 09 Jun 2025 | Direct | ||
| Cheryl Xu | SXTP | Common Stock | Purchase | 46.2% | $14,410 | $2.88 | 5,000 | 15,816 | 03 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.